RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07283796, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL).

    Inclusion criterion 3

    Agreement to undergo pathological tissue biopsy.

    Inclusion criterion 8

  3. No pregnancy plans from screening until at least 3 months after the last dose of the study drug, and voluntary use of effective contraceptive measures.

    Inclusion criterion 10

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.

    Inclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07283796, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form.
  • Age ≥18 years, with no gender restriction.
  • Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
  • Expected survival >3 months.
  • Presence of measurable lesions.
  • Adequate organ function.
  • Agreement to undergo pathological tissue biopsy.
  • Subjects of childbearing potential must agree to comply with the contraceptive requirements of the study.
  • No pregnancy plans from screening until at least 3 months after the last dose of the study drug, and voluntary use of effective contraceptive measures.

Exclusion Criteria:

  • Concurrent presence of other severe, unstable diseases/conditions that, in the investigator's judgment, make participation in this study unsuitable.
  • History of or current severe cardiovascular disease.
  • Poorly controlled blood pressure during the screening period.
  • Laboratory abnormalities identified by the investigator that may pose a risk to the subject's safety.
  • Electrocardiogram abnormalities determined by the investigator as potentially posing a risk to the subject's safety.
  • History of allergies to the investigational drug or its excipients.
  • Inability to discontinue prohibited medications as specified in the protocol during the screening period and throughout the entire study duration.
  • Any other conditions that may increase subject risk or interfere with the trial results.
  • Any other situations where the investigator deems the subject unsuitable for participation.

Quoted from ClinicalTrials.gov, NCT07283796, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07283796, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07283796